Ananda J Thomas, Janet Adegboye, Emmarie Myers, Anjana Sekaran, Una E Choi, Jana Christian, Elizabeth A Hendricks, Mellany Stanislaus, Jamie D Murphy, Ahizechukwu Eke, Arthur J Vaught, Linda M S Resar, Steven M Frank
{"title":"Management strategies and clinical outcomes of obstetric patients who decline allogeneic blood transfusion.","authors":"Ananda J Thomas, Janet Adegboye, Emmarie Myers, Anjana Sekaran, Una E Choi, Jana Christian, Elizabeth A Hendricks, Mellany Stanislaus, Jamie D Murphy, Ahizechukwu Eke, Arthur J Vaught, Linda M S Resar, Steven M Frank","doi":"10.1111/vox.70061","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Providing obstetrical care for patients who decline transfusions can be challenging. We describe methods of coordinated bloodless care and compare outcomes to a similar group of patients who accept transfusions.</p><p><strong>Materials and methods: </strong>This retrospective analysis included obstetric Jehovah's Witness patients (bloodless group) from 2012 to 2023. We performed cohort matching in a 1:2 ratio with patients who accept transfusion (standard care), based on race, ethnicity, age, gestational age, body mass index and delivery mode (vaginal vs. caesarean section). Methods of blood conservation and clinical outcomes were compared between groups.</p><p><strong>Results: </strong>There were 131 bloodless and 262 standard care deliveries. There were no maternal mortalities in either group, and no difference in morbid events (1.5% of bloodless deliveries vs. 0.8% of standard care deliveries; p = 0.608). Prenatal intravenous iron was given more frequently in the bloodless compared with the standard care group (13.7% vs. 4.6%, p = 0.002). Second-line uterotonics were used more frequently in bloodless compared with standard care deliveries (44.3% vs. 29.0%, p = 0.021). Albumin was also more frequently given in bloodless compared with standard care deliveries (5.3% vs. 1.5%, p = 0.047). Cell salvage was present for 67.3% of the bloodless group but was not utilized for any standard care deliveries (p < 0.001). None of the bloodless patients received a red blood cell transfusion, while 10 standard care deliveries (3.8%) were transfused (p = 0.035).</p><p><strong>Conclusion: </strong>Obstetric patients who decline allogeneic transfusions can be effectively managed with bloodless medicine techniques with acceptable outcomes.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"904-912"},"PeriodicalIF":1.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vox Sanguinis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/vox.70061","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objectives: Providing obstetrical care for patients who decline transfusions can be challenging. We describe methods of coordinated bloodless care and compare outcomes to a similar group of patients who accept transfusions.
Materials and methods: This retrospective analysis included obstetric Jehovah's Witness patients (bloodless group) from 2012 to 2023. We performed cohort matching in a 1:2 ratio with patients who accept transfusion (standard care), based on race, ethnicity, age, gestational age, body mass index and delivery mode (vaginal vs. caesarean section). Methods of blood conservation and clinical outcomes were compared between groups.
Results: There were 131 bloodless and 262 standard care deliveries. There were no maternal mortalities in either group, and no difference in morbid events (1.5% of bloodless deliveries vs. 0.8% of standard care deliveries; p = 0.608). Prenatal intravenous iron was given more frequently in the bloodless compared with the standard care group (13.7% vs. 4.6%, p = 0.002). Second-line uterotonics were used more frequently in bloodless compared with standard care deliveries (44.3% vs. 29.0%, p = 0.021). Albumin was also more frequently given in bloodless compared with standard care deliveries (5.3% vs. 1.5%, p = 0.047). Cell salvage was present for 67.3% of the bloodless group but was not utilized for any standard care deliveries (p < 0.001). None of the bloodless patients received a red blood cell transfusion, while 10 standard care deliveries (3.8%) were transfused (p = 0.035).
Conclusion: Obstetric patients who decline allogeneic transfusions can be effectively managed with bloodless medicine techniques with acceptable outcomes.
期刊介绍:
Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections:
1) Transfusion - Transmitted Disease and its Prevention:
Identification and epidemiology of infectious agents transmissible by blood;
Bacterial contamination of blood components;
Donor recruitment and selection methods;
Pathogen inactivation.
2) Blood Component Collection and Production:
Blood collection methods and devices (including apheresis);
Plasma fractionation techniques and plasma derivatives;
Preparation of labile blood components;
Inventory management;
Hematopoietic progenitor cell collection and storage;
Collection and storage of tissues;
Quality management and good manufacturing practice;
Automation and information technology.
3) Transfusion Medicine and New Therapies:
Transfusion thresholds and audits;
Haemovigilance;
Clinical trials regarding appropriate haemotherapy;
Non-infectious adverse affects of transfusion;
Therapeutic apheresis;
Support of transplant patients;
Gene therapy and immunotherapy.
4) Immunohaematology and Immunogenetics:
Autoimmunity in haematology;
Alloimmunity of blood;
Pre-transfusion testing;
Immunodiagnostics;
Immunobiology;
Complement in immunohaematology;
Blood typing reagents;
Genetic markers of blood cells and serum proteins: polymorphisms and function;
Genetic markers and disease;
Parentage testing and forensic immunohaematology.
5) Cellular Therapy:
Cell-based therapies;
Stem cell sources;
Stem cell processing and storage;
Stem cell products;
Stem cell plasticity;
Regenerative medicine with cells;
Cellular immunotherapy;
Molecular therapy;
Gene therapy.